Purpose: Women with breast cancer report varying frequencies of cognitive problems during adjuvant systemic therapy. This variability suggests latent subgroups. Therefore, we identified latent subgroups of self-reported cognitive problems among postmenopausal women with and without breast cancer. We explored associations between membership in these subgroups and (a) demographic, clinical, and symptom characteristics and (b) variations in candidate gene polymorphisms. Methods: We evaluated frequency of cognitive problems using the Patient Assessment of Own Functioning Inventory. Growth mixture modeling identified latent subgroups over 18 months of adjuvant systemic therapy and at matched time points for women without cancer (N ¼ 331). We evaluated for differences among subgroups in demographic, clinical, and symptom characteristics and in 41 single nucleotide polymorphisms in 10 candidate genes involved in DNA repair and oxidative stress pathways (n ¼ 199). We modeled associations between genotypes and subgroup membership using multinomial logistic regression. Results: We identified three latent subgroups: more frequent, persistent, and almost never. Receipt of chemotherapy plus anastrozole, depressive symptoms, and baseline neuropathic symptoms increased the odds of belonging to the more frequent subgroup. Anxiety and depressive symptoms increased the odds of belonging to the persistent subgroup. With covariates controlled for, carrying the ERCC5 rs873601 G minor allele increased the odds of reporting more frequent cognitive problems. Conclusions: Chemotherapy plus anastrozole, depressive symptoms, and presence of neuropathic symptoms may predict more frequent cognitive problems during systemic therapy that later resolve. Mood dysregulation before therapy may predict persistent cognitive problems during therapy. ERCC5 genotype may influence frequency of cognitive problems after controlling for these risk factors.
Over a quarter of a million women in the United States, most of whom were postmenopausal, received a diagnosis of invasive breast cancer in 2017 (American Cancer Society, 2017) . Some who report cognitive problems related to their diagnosis and its treatment will experience difficulty with planning and carrying out tasks (Bruno, Hosseini, & Kesler, 2012) , reduced speed in performing mental tasks , and difficulty with sustained attention (Berman et al., 2014; Mandelblatt et al., 2016 ) and short-term memory (Bruno et al., 2012; Collins, Paquet, Dominelli, White, & MacKenzie, 2017; Ganz et al., 2013; Mandelblatt et al., 2016) . These cognitive problems are an important quality-of-life concern for cancer survivors (Boykoff, Moieni, & Subramanian, 2009 ).
We previously found that cognitive problems reported by postmenopausal women with breast cancer increase in frequency after adjuvant chemotherapy and persist during the first year of aromatase inhibitor (AI) therapy. In contrast, we found that cognitive problems do not increase in frequency during AI therapy alone (Merriman et al., 2017) . However, the frequency of cognitive problems reported by patients receiving different cancer therapies (Ahles, Root, & Ryan, 2012) or even the same therapies (Mandelblatt et al., 2016) varies significantly. This variability suggests the presence of latent subgroups such that members in each have similar trajectories for their cognitive problems that do not necessarily depend on therapies received (Mandelblatt et al., 2016) or the diagnosis of cancer. Taking such an agnostic approach does not assume that cancer and its therapies are the cause of cognitive problems. The identification of latent subgroups in samples composed of women with and without breast cancer can uncover demographic, clinical, and biological correlates of trajectories of cognitive problems. For example, cognitive problems could be associated with menopause (Takahashi & Johnson, 2015) or other biological (Ahles et al., 2012) or psychological factors (Berman et al., 2014) . Patient characteristics such as these are potentially useful for clinical prediction of cognitive problems during therapy and may inform hypotheses for underlying mechanisms.
One mechanistic hypothesis for cognitive problems is accelerated aging (Ahles & Hurria, 2017) . Cognitive problems associated with normal aging are due, in part, to an accumulation of unrepaired damage to the deoxyribonucleic acid (DNA) of neurons in the central nervous system by oxidative stress (Mandelblatt et al., 2013) . Conroy et al. (2013) found greater oxidative DNA damage and lower gray matter density for breast cancer survivors an average of 6 years after chemotherapy versus noncancer controls, suggesting that these survivors may have cognitive problems due to unrepaired neuronal damage.
The efficiency of DNA repair in response to damage caused by oxidative stress could influence the extent of neuronal damage sustained during systemic cancer therapies (Janelsins, Kesler, Ahles, & Morrow, 2014) . Variability in efficiency may be due, in part, to polymorphisms in candidate genes involved in DNA repair and oxidative stress pathways (Koleck et al., 2016) . Therefore, distributions of alleles for single nucleotide polymorphisms (SNPs) in these candidate genes may be associated with the frequency of cognitive problems.
For example, apolipoprotein E (APOE) is a pleiotropic gene involved in oxidative stress pathways. The antioxidant properties of the APOE protein are isoform dependent (i.e., E2 > E3 > E4; Jofre-Monseny, Minihane, & Rimbach, 2008) . Older adults who carry the epsilon 4 allele (E4) may perform more poorly on neuropsychological tests (Langbaum et al., 2013) . Ahles et al. (2003) found that the E4 allele was associated with poorer visual memory and spatial ability in breast cancer and lymphoma survivors who received chemotherapy and that smoking history interacted with the E4 allele to influence processing speed . Koleck et al. (2014) found poorer verbal memory for carriers of the E4 allele and noted an interaction with anastrozole therapy that negatively impacted executive function, visual memory, and attention.
The influence of genetic variability in these pathways on cognitive problems is not limited to women with breast cancer. For example, Cole et al. (2015) found that variability in genes involved in oxidative stress pathways was associated with poorer neuropsychological performance after chemotherapy for childhood leukemia. However, no studies reported on the relationship between variability in candidate genes involved in DNA repair and oxidative stress pathways and frequency of self-reported cognitive problems.
Therefore, the purposes of this study were to (1) identify latent subgroups of the frequency of self-reported cognitive problems among postmenopausal women with and without breast cancer and (2) explore associations between membership in latent subgroups and (a) baseline demographic, clinical, and symptom characteristics and (b) variations in candidate genes involved in DNA repair and oxidative stress pathways.
Materials and Method
This analysis is part of a larger study (Bender et al., 2015; Merriman et al., 2017 ) that evaluated cognitive problems in postmenopausal women with and without breast cancer (R01CA107408). The Human Research Protection Office of the University of Pittsburgh approved the study.
Study Procedures
Study staff recruited 331 participants, which included 209 women with early-stage (Stages I-IIIa) invasive breast cancer from the Magee-Women's Breast Cancer Program and 122 age-and education-matched women without breast cancer, using advertisements, referral from patients, and randomdigit dialing. All participants were postmenopausal, 75 years of age (due to concerns of more severe cognitive problems with advancing age), and literate in English. They had no other cancers except nonmelanoma skin cancer, no recent hospitalizations for psychiatric disorders, and no neurological disorders. Patients had completed surgical management.
After providing written informed consent, patients completed a baseline assessment before beginning systemic therapy (i.e., the AI anastrozole alone or chemotherapy followed by anastrozole). Study staff assessed patients every 6 months for up to 18 months after the start of systemic therapy (four assessments in total). We assessed women without breast cancer, for whom the baseline assessment was considered to be the enrollment assessment, at matched time points. Additional funding secured after primary data collection began facilitated genetic data collection from consenting participants (n ¼ 199).
Instruments
We evaluated frequency of self-reported cognitive problems using the Patient Assessment of Own Functioning Inventory (PAOFI; Chelune, Heaton, & Lehman, 1986) . For each of 32 items that asked how often participants experienced problems in the domains of memory, language and communication, use of hands/sensory-perceptual, and higher-level cognitive and intellectual functions, participants rated frequency of cognitive problems on a 6-point scale ranging from 0 (almost never) to 5 (almost always). Higher summed scores indicate more frequent cognitive problems. Van Dyk, Ganz, Ercoli, Petersen, and Crespi (2016) reported a potential clinically meaningful cutoff for a total score composed of a different number of items and using an individual item score range of 1-6. These differences prevent use of their proposed cutoff score in the present study. Previous studies have used the PAOFI in women with breast cancer (Ercoli et al., 2015; Ganz et al., 2013; 2014) . The PAOFI has acceptable construct (Bell, Terhorst, & Bender, 2013; Van Dyk, Ganz, Ercoli, Petersen, & Crespi, 2016) (Bender et al., 2015) .
Genotyping
We recovered DNA from 199 of the participants (i.e., 121 patients, 78 women without breast cancer) using a salting-out procedure for whole blood samples and the Oragene DNA kit (DNA Genotek, Ottawa, Ontario) for saliva samples. We selected tagging SNPs using HapMap 3 and derived functional SNPs from the literature. The iPLEX MassARRAY multiplex assay platform (Sequenom, San Diego) or TaqMan allelic discrimination (Thermo Fisher Scientific, Waltham, MA) genotyped 41 SNPs. These polymorphisms included 24 SNPs in four candidate genes involved in DNA repair (i.e., four in PARP1, eight in ERCC2, four in ERCC3, and eight in ERCC5) and 17 SNPs in six candidate genes involved in oxidative stress (i.e., three in SEPP1, three in SOD2, seven in CAT, one each in SOD1 and GPX1, and two that determine APOE allele status [i.e., rs429358, rs7412]). We included positive and negative controls. Two study investigators independently called (i.e., determined) all genotypes, blinded to participant phenotypes. For discrepant calls, the investigators reviewed raw data or regenotyped samples. We tested SNPs for deviations from Hardy-Weinberg expectations using a w 2 goodness-of-fit test. Sample sizes reported for each SNP vary due to the success of each assay. For full details of gene and SNP selection and methods for DNA recovery and genotyping, see Koleck et al. (2014 Koleck et al. ( , 2016 .
Latent Subgroup Analysis
We employed growth mixture modeling (GMM) using Mplus Version 7.4 (Muthén & Muthén, Los Angeles) to identify latent classes (i.e., subgroups) of PAOFI total score trajectories among all participants (N ¼ 331). We modeled our approach to GMM on that of Dunn et al. (2012) . In brief, we evaluated multiple models for PAOFI scores using robust maximum likelihood estimation with random intercepts and random slopes to determine the optimal number of subgroups and their intercepts and trajectories. Robust maximum likelihood retained all participants when missing data were present using the expectation-maximization algorithm (Schafer & Graham, 2002) . We determined the optimal number of subgroups based on the smallest Bayesian information criterion, highest entropy, a significant bootstrapped likelihood ratio test, and a Vuong-Lo-Mendell-Rubin likelihood ratio test indicating that the k-class solution fit the data better than the (k minus 1)-class solution. Each class maintained reasonable posterior probability, size, and interpretability.
Statistical Analyses
Bivariate analyses. We used SPSS Statistics 24 (IBM, Armonk, NY) to generate descriptive statistics. We used analysis of variance and chi-square (w 2 ) to evaluate for differences among subgroups in demographic, clinical, and symptom characteristics as well as in minor allele frequencies for additive, dominant, and recessive genetic models for each SNP (n ¼ 199). We selected the genetic model that best fit the data by maximizing the significance of the p value when we found a significant difference in minor allele frequency. For variables with nonnormal distributions after transformation, we used nonparametric tests. If expected cell counts were sparse, we used Fisher's exact (FE) test. We considered overall differences statistically significant at p < .05 and adjusted post hoc pairwise subgroup comparisons using either the Bonferroni or Tamhane correction, as appropriate.
Multivariable analyses. Variables found to be significant in bivariate analyses were considered further in multivariable analyses (n ¼ 199). We first used multinomial logistic regression in Stata/SE 14 (StataCorp, College Station, TX) to identify associations between demographic, clinical, and symptom characteristics and subgroup membership. Using a backward stepwise approach, we retained correlates with overall p values <.05 in an initial multivariable model. We evaluated for possible confounding for variables removed during this process that had significant correlations >.25 with variables retained in the initial multivariable model.
Controlling for variables in the initial multivariable model, we explored associations between minor allele distributions of SNPs found to be significant in the bivariate analysis and subgroup membership. Due to the exploratory nature of this candidate gene association study and the a priori nature of the candidate genes selected (i.e., having high prior odds of an association with cognitive problems during systemic therapy), we did not adjust for testing in multiple candidate genes. We retained self-reported race in the final model to adjust for potential confounding due to population stratification. We retained genotypic correlates with overall p values <.05. Within each genotypic model, for each of j possible pairwise subgroup comparisons, we considered p < .05/j statistically significant (i.e., Bonferroni correction). We determined covariate-adjusted odds ratios and 95% confidence intervals for significant variables in the final models.
Results

Latent Subgroups
A three-subgroup solution for PAOFI total score best fit the data (Table 1 ; N ¼ 331). These subgroups (Figure 1 ) included (1) more frequent cognitive problems reported through the first year of adjuvant therapy then improving (more frequent; 8.8%), (2) infrequent but persistent cognitive problems (persistent; 16.3%), and (3) almost never reporting cognitive problems (almost never; 74.9%). Table 2 shows model-estimated values for each of the subgroups.
Participants in the more frequent subgroup had a mean baseline PAOFI total score of 27.0 (SD ¼ 12.01) that increased (indicating more frequent cognitive problems) during the first 6 months, stabilized, and decreased between 12 and 18 months. They reported lower scores than the persistent subgroup at baseline but reported higher scores than this subgroup within 6 months of beginning therapy. The persistent subgroup had a mean baseline score of 36.7 (SD ¼ 13.84) that remained stable. The almost never subgroup had a mean baseline score of 14.2 (SD ¼ 8.68) that remained stable.
Demographic, Clinical, and Symptom Correlates of Latent Subgroup Membership
We previously reported demographic, clinical, and symptom characteristics of the full sample (Merriman et al., 2017) , so this report will focus on differences in these characteristics among the latent subgroups. At baseline, we found significant differences among the latent subgroups in age, verbal IQ score, treatment type, and stage of breast cancer (Table 3) . We found no differences in the proportions of patients versus controls. We found significant differences in the presence of pain and neuropathic symptoms and in POMS fatigue/inertia, POMS tension/anxiety, and BDI-II scores (Online Supplemental Table 1 ). We found no differences in neuropsychological performance (Online Supplemental Table 2 ). Participants who did not complete the study (n ¼ 20, 10.1%) reported higher POMS fatigue/inertia scores (median
In the initial multivariable model ( presence of neuropathic symptoms at baseline (p < .001) had overall associations with subgroup membership. Receipt of chemotherapy plus anastrozole increased odds of belonging to the more frequent versus almost never subgroup. Higher POMS tension/anxiety scores increased the odds of belonging to the persistent versus more frequent subgroup. Higher BDI-II scores increased the odds of belonging to the more frequent or persistent versus almost never subgroup. Presence of neuropathic symptoms increased the odds of belonging to the more frequent versus almost never subgroup. Using the Bonferroni correction, p < .0167 is considered significant (indicated by *). For POMS tension/anxiety and BDI-II scores, adjusted odds ratios are reported per one-unit increase in scores. BDI-II ¼ Beck Depression Inventory II; CI ¼ confidence interval; ERCC5 ¼ ERCC excision repair 5, endonuclease; GMM ¼ growth mixture model. a Self-reported race was retained to adjust for potential confounding due to population stratification (data not shown). Patient status was retained to control for the diagnosis of breast cancer (data not shown). The genotypic correlate evaluated was ERCC5 rs873601 (AG þ GG vs. AA). multivariable model, carrying at least one copy of the G minor allele for rs873601 increased women's odds of belonging to the more frequent versus almost never subgroup (p ¼ .013). Figure  2 depicts this SNP's minor allele distribution. ERCC5 rs2296147 (p ¼ .074) and CAT rs769214 (p ¼ .165) genotypes were not associated with subgroup membership in multivariable models.
Discussion
Our findings provide evidence of subgroups of postmenopausal women with distinct trajectories of the frequency of selfreported cognitive problems. The proportion of participants in the more frequent subgroup is similar to the results reported in other studies (i.e., approximately 7-9%; Amidi et al., 2015; Mandelblatt et al., 2016) . Unlike our finding that this subgroup began to improve by 18 months after initiation of AI therapy, Mandelblatt et al. (2016) identified an accelerated decline subgroup that did not improve within this time frame. The divergent trajectories may result from a number of differences between the studies. Mandelblatt et al. used 2 items from a larger quality-oflife questionnaire to model change in severity of self-reported cognitive function, whereas in the present study we used a comprehensive cognitive questionnaire to model change in frequency. Moreover, the present study included younger postmenopausal women. Amidi et al. (2015) observed that this proportion approximates older population norms (i.e., aged 65-74 years). However, in the present study, the more frequent subgroup had an average age of 56.7 years (SD ¼ 6.54), which was younger than the mean age for the other studies. With all findings taken together, it is possible that the more frequent cognitive problems this subgroup reported during therapy were due in part to accelerated aging (Ahles & Hurria, 2017) .
However, although the more frequent subgroup reported more frequent cognitive problems over the first 6 months of the study, the frequency stabilized and began to improve by 18 months. It is possible that the improvement seen after the first year of therapy may be attributable to slow recovery from the effects of systemic therapy on cognitive function, which may be consistent with inefficient DNA repair. It is also possible that this subgroup experienced a response shift in their evaluation of these more frequent cognitive problems as they adapted their expectations for cognitive function over time (Gerlich et al., 2016) .
The persistent subgroup reported greater frequency of cognitive problems than the other subgroups at baseline. Unlike for the more frequent subgroup, this frequency did not change, which suggests that pretherapy factors influence this trajectory. Almost three quarters of the sample belonged to the almost never subgroup, which suggests that many women do not report or do not notice cognitive problems during breast cancer therapy. This proportion is similar to the findings of Ganz et al. (2013) , who used the same instrument. In contrast, Mandelblatt et al. (2016) found 42% of patients with a trajectory similar to that of the almost never subgroup, suggesting that most older women with breast cancer report some degree of cognitive problems. Across the literature, the proportion of patients at risk of cognitive problems varies considerably (Janelsins et al., 2014) . These discrepancies might be explained by methodological differences among studies (Ahles & Hurria, 2017) , including differing measures of self-reported or objective neuropsychological function, assessment time points, and characteristics of samples. Our findings in the present study suggest that about a quarter of postmenopausal women with breast cancer report cognitive problems associated with the risk factors described below.
Demographic, Clinical, and Symptom Correlates of Latent Subgroup Membership
Receipt of chemotherapy plus anastrozole, presence of neuropathic symptoms at baseline, and greater baseline levels of depressive symptoms correlated with membership in the more frequent subgroup. Receipt of chemotherapy correlated with poorer cognitive function in numerous studies (Janelsins et al., 2014) . For example, Janelsins et al. (2016) found that women receiving chemotherapy for breast cancer reported more cognitive problems than age-matched controls after chemotherapy and 6 months later, when adjusting for menopausal status. Less clear is the relationship between anastrozole and cognitive function. AI therapy does not appear to impact cognitive functioning in at-risk women taking it as chemoprevention (Jenkins et al., 2008) . Studies including pre-and postmenopausal women taking either tamoxifen or AIs for breast cancer found mixed effects on cognitive function (Breckenridge, Bruns, Todd, & Feuerstein, 2012; Ganz et al., 2014; Janelsins et al., 2016; Ribi et al., 2012) . Anastrozole alone impacted neuropsychological performance in postmenopausal women with breast cancer (Bender et al., 2015) but not their self-reported cognitive function (Merriman et al., 2017; Schilder et al., 2012) . By reducing already low estrogen levels, receipt of anastrozole after chemotherapy may downregulate neurogenesis that facilitates the repair of chemotherapyinduced neuronal damage (Ahles et al., 2012) . This hypothesized effect may contribute to the association between adjuvant systemic therapy and membership in the more frequent subgroup we found in the current study. Higher levels of depressive symptoms and anxiety were significantly associated with membership in the persistent subgroup. Because none of the correlates of membership in the persistent subgroup were specific to women with breast cancer, this latent subgroup may capture patients who enter systemic therapy with preexisting cognitive problems associated with mood dysregulation. This finding suggests that pretherapy mood dysregulation could account for their cognitive problems during therapy. Mood dysregulation is often a correlate of self-reported cognitive problems (Berman et al., 2014; Janelsins et al., 2016) . Participants in the two at-risk subgroups reported low levels of depressive symptoms at baseline. Although not typically clinically actionable, addressing even low levels of depressive symptoms, particularly when they present concurrently with anxiety, may alleviate cognitive problems during therapy.
The association between neuropathic symptoms before systemic therapy and membership in the more frequent subgroup is intriguing. It suggests that neuropathic symptoms before systemic therapy may indicate susceptibility to central nervous system damage during therapy. Similarly, Myers, Wick, and Klemp (2015) found relationships between neuropathy and poorer self-reported cognitive function before chemotherapy for breast cancer.
Genotypic Correlates of Latent Subgroup Membership
In exploratory multivariable models that controlled for receipt of chemotherapy plus anastrozole, baseline anxiety and depressive symptoms, and presence of neuropathic symptoms at baseline, the association between ERCC5 rs873601 genotype and subgroup membership that we found in the bivariate analysis remained. Variations in other DNA repair and oxidative stress candidate genes did not correlate with subgroup membership in multivariable models.
Carrying the G minor allele at rs873601 conferred increased risk of membership in the more frequent subgroup. This SNP is in the 3 0 untranslated region of ERCC5 and, therefore, may influence gene expression (He et al., 2012) . Because ERCC5 encodes a DNA excision repair endonuclease, its variable expression may impact efficiency of DNA repair during adjuvant therapy. Koleck et al. (2016) found poorer pretherapy neuropsychological performance for carriers of the G minor allele in the same sample. Zhou et al. (2016) found poorer survival for patients with esophageal cancer who carried the G allele. Other studies found protective effects for the G minor allele, including reduced risk of gastric cancer (Chen et al., 2016; He et al., 2012) and improved response to chemotherapy (Hu, Pan, Zhao, Yang, & Yang, 2014) . Improved response to chemotherapy and poorer cognitive function may be consistent, as greater destruction of tumor cells may increase risk of neuronal damage. However, reduced risk of gastric cancer does not fit this hypothesis. It is possible that risks for carriers of the G allele vary by population. The current sample was primarily of European descent, while the other studies were done in samples of Han Chinese. While the G minor allele frequency for Han Chinese (CHB) is 47.6%, the minor allele frequency in our sample was 31.6%, which is similar for people of European descent (CEU) (1000 Genomes Project Consortium, 2015 . Furthermore, rs873601 is in linkage disequilibrium with rs17655, a nonsynonymous SNP, and rs9554903, a transcription factor-binding site, for CHB but not CEU populations (Xu & Taylor, 2009 ). An alternative hypothesis is that differences in systemic therapies between women with breast cancer, who receive AI therapy, and patients with gastric cancer, who do not receive antiestrogen therapy, interact with genotype to influence outcomes.
A surprising finding was that carrying the APOE E4 allele did not increase the odds of more frequent cognitive problems among postmenopausal women in our sample. In contrast, although the average ages of participants in the studies were similar, Ahles et al. (2003) reported an inverse relationship between carrying the APOE E4 allele and objective neuropsychological performance. In middle-aged women, however, before mild cognitive impairment or dementia are typically diagnosed, subjective instruments may be less sensitive to cognitive changes associated with the APOE E4 allele (KrellRoesch et al., 2015) .
Limitations and Implications
In this exploratory study, we did not evaluate variability in all genes important in DNA repair and oxidative stress nor all genes potentially impacting self-reported cognitive problems. Instead, we focused on candidate biological pathways that may be involved in cognitive problems reported by breast cancer patients. The sample that provided DNA comprised participants who reported slightly less frequent cognitive problems than did participants as a whole in the larger study, which may have biased findings toward the null hypothesis. We did not control the number of bivariate tests for genetic variants for multiple testing due to the modest sample size for candidate gene association studies and the higher prior odds of candidate gene associations with cognitive problems during systemic therapy. It is possible that our exploratory genetic findings are due to chance. We did not have genomic estimates of race and ethnicity (i.e., ancestry informative markers). This exploratory study provides preliminary evidence of an association between variation in ERCC5 and the frequency of self-reported cognitive problems. This preliminary finding warrants replication in an independent sample, and functional relationships between this SNP and frequency of cognitive problems during therapy should be evaluated before clinical implications are considered.
Despite these limitations, our findings suggest that chemotherapy plus anastrozole, low levels of depressive symptoms, and neuropathic symptoms before therapy may predict worsening cognitive problems that may improve with time. Unresolved mood dysregulation before systemic therapy may predict persistent cognitive problems throughout therapy. When accounting for these risk factors, variability in DNA repair efficiency could influence frequency of cognitive problems.
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